(b) a sufficient amount of a hydroxypropyl-β-cyclodextrin having an M.S. in the range of 0.3 to 3 and containing less than 5% unsubstituted β-cyclodextrin, to act as a solubilizer for the itraconazole or saperconazole;

(c) an aqueous acidic medium as bulk liquid carrier;

C 1

(d) from about 1% (v/v) to about 20% (v/v) of an alcoholic co-solvent selected from the group consisting of ethanol, propylene glycol and glycerol;

(e) one or more pharmaceutically acceptable intense sweeteners plus one or more bulk sweeteners; and

(f) one or more pharmaceutically acceptable flavors.

REMARKS

Reconsideration of this application in its amended form is respectfully requested.

Claim 11 has been amended to add the limitation that the alcoholic co-solvent is present in an amount of from about 1% to about 20% (v/v), in order to more clearly distinguish the claimed invention over Heeres et al., U.S. Patent No. 4,916,134, which discloses (in Example 13) a formulation containing about 60% glycerol. Basis for this amendment to the claims is found in the specification at page 4, lines 29-32.

15